A weight-loss pill sounds easier than an injection. No needles, and perhaps a simpler routine. But choosing a treatment based on how you take it misses the bigger question: What does the medicine actually do?
Some weight-loss drugs reduce the amount of fat your body absorbs. Others affect the signals that control hunger and fullness. Both types can come as pills, so comparing pills with injections doesn’t always tell you much about how the treatments work. If you’re weighing your options, the most useful comparison involves the specific medicines, their results, potential side effects, and the cost of continuing treatment.
How Do Weight-Loss Pills and Injections Work?
Orlistat works in your digestive system. It blocks some of the enzymes that break down fat in food. Your body then absorbs less of that fat. However, orlistat doesn’t directly reduce your appetite.
Other treatments work differently. Semaglutide, the ingredient in Wegovy, acts on a hormone pathway called GLP-1, which helps regulate appetite. Tirzepatide, sold for weight management as Zepbound, acts on two hormone pathways, GLP-1 and GIP. These medicines can help people feel full sooner and eat less (Novo Nordisk Inc., 2026; Eli Lilly and Company, 2026).
Until recently, people mainly associated appetite-reducing medicines with injections. That’s changing. The FDA approved a Wegovy pill in December 2025 and another GLP-1 pill, Foundayo (orforglipron), in April 2026 (Novo Nordisk A/S, 2025; U.S. Food and Drug Administration [FDA], 2026).
Here’s the main difference: Orlistat reduces the amount of fat your body absorbs from food. GLP-1 medicines help control appetite, whether you take them as pills or injections. This doesn’t mean every GLP-1 treatment produces the same results. The ingredients, doses, and side effects still differ.
What’s Taking Orlistat Actually Like?
Prescription orlistat 120 mg comes with a straightforward instruction: Take one capsule with each main meal containing fat, up to three times daily. Skip the dose when you miss a meal or eat a fat-free meal. Doctors prescribe it alongside a reduced-calorie eating plan (H2-Pharma LLC, 2026).
Consider lunch. If you eat a sandwich with cheese or dressing, orlistat can reduce how much fat your body absorbs from that meal. However, it won’t stop you from feeling hungry later, and it won’t prevent your body from absorbing all the calories you consume.
If you’re considering oral weight-loss medication, check out the directions for use, dietary considerations, and side effects of orlistat 120mg capsules. The information provides a practical look at using orlistat, although you should still seek medical advice before starting treatment. Consult a US-licensed healthcare professional and obtain prescription medication through a properly licensed pharmacy.
What Does the Research Say About Weight Loss?
Clinical trials show that orlistat and several injectable treatments can help people lose weight. However, the amount of weight participants lost varied considerably between studies.
In a four-year study, participants taking orlistat alongside lifestyle changes lost an average of 5.8 kilograms (approximately 13 pounds). Those taking a placebo while making similar lifestyle changes lost an average of 3.0 kilograms (approximately 7 pounds) (Torgerson et al., 2004).
Research into injectable treatments has reported larger average reductions in body weight. In a 68-week trial, participants without diabetes who received weekly semaglutide injections lost an average of 14.9% of their starting body weight. Participants receiving a placebo lost 2.4% (Wilding et al., 2021).
Similarly, a 72-week study found that participants taking tirzepatide lost an average of 15.0% to 20.9% of their starting weight, depending on their dose. The placebo group lost 3.1% (Jastreboff et al., 2022). These findings suggest that the injectable medicines studied can produce greater average weight loss than orlistat.
However, researchers conducted these trials separately, with different participants and study durations. The results don’t provide a direct comparison between these medicines, and they can’t predict exactly how much weight an individual will lose.
How Do the Side Effects Compare?
Side effects can affect whether someone feels comfortable continuing treatment. Orlistat commonly causes oily stools, gas, and an urgent need to use the bathroom. High-fat meals can worsen these symptoms. The medicine can also reduce the absorption of vitamins A, D, E, and K. Doctors may recommend taking a multivitamin at a different time of day (H2-Pharma LLC, 2026).
GLP-1 medicines have different side effects. People may experience nausea, vomiting, diarrhea, constipation, or stomach pain, particularly when increasing their dose.
Some treatments also carry warnings about pancreatitis and gallbladder problems. Wegovy and Zepbound carry boxed warnings about thyroid tumors observed in animal studies. Researchers haven’t established whether these medicines cause the same tumors in humans, but doctors avoid prescribing them to people with certain personal or family medical histories (Novo Nordisk Inc., 2026; Eli Lilly and Company, 2026).
It’s also important to review any medicines you already take. For example, orlistat can interfere with medications such as levothyroxine and cyclosporine. A pill isn’t automatically safer than an injection. Your medical history and the medicine’s ingredients matter more than how you take it.
Which Treatment Fits Your Lifestyle and Budget?
A treatment may work well in a clinical trial but prove difficult to manage in everyday life. Weekly injections might suit someone who prefers fewer doses. Orlistat requires more attention throughout the day because you take it around meals.
Even oral medicines have different instructions. For example, oral Wegovy requires patients to take it on an empty stomach and wait before eating or taking other oral medications. Foundayo doesn’t have the same food restrictions (Novo Nordisk Inc., 2026; FDA, 2026).
Cost is another consideration. Insurance plans don’t always cover weight-loss medications, and coverage can vary between treatments. Before choosing a prescription, check your monthly out-of-pocket costs, insurance requirements, and any expenses associated with follow-up appointments. Ask your clinician how they will monitor your progress and decide whether the treatment remains appropriate.
Weight-loss pills and injections don’t all work in the same way. Orlistat reduces fat absorption, while GLP-1 medicines affect appetite. Clinical trials also show differences in average weight loss, although individual results vary.
Neither approach suits everyone. Before starting treatment, discuss your health history, existing medications, and weight-management goals with a qualified healthcare professional. Ask about realistic results, potential side effects, ongoing costs, and how long treatment might continue.
Medication should also form part of a broader plan that considers nutrition, physical activity, and long-term health. Rather than choosing a treatment simply because it comes as a pill or injection, focus on which medicine offers an appropriate balance of benefits and risks for your circumstances.
● Eli Lilly and Company. (2026). Zepbound (tirzepatide) injection: Prescribing information. DailyMed.
● H2-Pharma LLC. (2026). Orlistat capsules: Prescribing information. DailyMed.
● Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. The New England Journal of Medicine, 387(3), 205–216.
● Novo Nordisk A/S. (2025, December 22). Wegovy pill approved in the US as first oral GLP-1 for weight management [Press release].
● Novo Nordisk Inc. (2026). Wegovy (semaglutide) injection and tablets: Prescribing information. DailyMed.
● Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161.
● U.S. Food and Drug Administration. (2026, April 1). FDA approves first new molecular entity under National Priority Voucher Program.
● Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384(11), 989–1002.